ArticleThe Journal of antimicrobial chemotherapy2012
A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.
Article in The Journal of antimicrobial chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 82 citations in OpenAlex.
- Alternative ribosome expression alone is insufficient to drive antibiotic tolerance inFrontiers in microbiology · 2026Article
- GlnA3Journal of bacteriology · 2025Article
- Synthesis and Antimycobacterial Assays of Some New Ethambutol Analogs.Molecules (Basel, Switzerland) · 2025Article
- Different mCherry isoforms show distinct photophysical properties in FRET tandem constructs.Frontiers in bioengineering and biotechnology · 2025Article
- Spermine enhances the activity of anti-tuberculosis drugs.Microbiology spectrum · 2024Article
- A feasibility study of controlled human infection with intradermal Bacillus Calmette-Guérin (BCG) injection: Pilot BCG controlled human infection model.Wellcome open research · 2023Article
- Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis.ACS infectious diseases · 2022Article
- Lipobiotin-capture magnetic bead assay for isolation, enrichment and detection of Mycobacterium tuberculosis from saliva.PloS one · 2022Article
- Macroscopic Fluorescence Lifetime Imaging for Monitoring of Drug-Target Engagement.Methods in molecular biology (Clifton, N.J.) · 2022Article
- WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis.The Journal of clinical investigation · 2021Article
- From Mouse to Man and Back: Closing the Correlation Gap between Imaging and Histopathology for Lung Diseases.Diagnostics (Basel, Switzerland) · 2020Review
- Article
- In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Monitoring Tuberculosis Drug Activity in Live Animals by Near-Infrared Fluorescence Imaging.Antimicrobial agents and chemotherapy · 2019Article
- Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis.The Journal of antibiotics · 2019Article
- Codon-optimized DsRed fluorescent protein for use in Mycobacterium tuberculosis.BMC research notes · 2018Article
- Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.BMC research notes · 2018Article
- Discovery of a cofactor-independent inhibitor ofLife science alliance · 2018Article
- Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence.Journal of visualized experiments : JoVE · 2018Article
- Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.ACS infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe current method for testing new drugs against tuberculosis in vivo is the enumeration of bacteria in organs by cfu assay. Owing to the slow growth rate of Mycobacterium tuberculosis (Mtb), these assays can take months to complete. Our aim was to develop a more efficient, fluorescence-based imaging assay to test new antibiotics in a mouse model using Mtb reporter strains.
methodsA commercial IVIS Kinetic® system and a custom-built laser scanning system with fluorescence molecular tomography (FMT) capability were used to detect fluorescent Mtb in living mice and lungs ex vivo. The resulting images were analysed and the fluorescence was correlated with data from cfu assays.
resultsWe have shown that fluorescent Mtb can be visualized in the lungs of living mice at a detection limit of ∼8 × 10⁷ cfu/lung, whilst in lungs ex vivo a detection limit of ∼2 × 10⁵ cfu/lung was found. These numbers were comparable between the two imaging systems. Ex vivo lung fluorescence correlated to numbers of bacteria in tissue, and the effect of treatment of mice with the antibiotic moxifloxacin could be visualized and quantified after only 9 days through fluorescence measurements, and was confirmed by cfu assays.
conclusionsWe have developed a new and efficient method for anti-tuberculosis drug testing in vivo, based on fluorescent Mtb reporter strains. Using this method instead of, or together with, cfu assays will reduce the time required to assess the preclinical efficacy of new drugs in animal models and enhance the progress of these candidates into clinical trials against human tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.